The current guidelines (ATA 2015, ESMO 2019) specify fine-needle aspiration (FNA) biopsy, ultrasound (US) of the neck, serum Ctn and CEA level analyses and RET gene mutation analysis as the most important for MTC detection and management. Here, CEACAM5 is linked to medullary thyroid gland carcinoma.